Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https://doi.org/10.1186/s13073-019-0703-1.
Article PubMed PubMed Central Google Scholar
Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52(2):177–86. https://doi.org/10.1038/s41588-019-0569-6.
Article CAS PubMed Google Scholar
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. https://doi.org/10.1056/NEJMoa0904554.
Article CAS PubMed Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. https://doi.org/10.1056/NEJMoa1913662.
Article CAS PubMed Google Scholar
Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–7. https://doi.org/10.1038/s41586-021-03898-1.
Article ADS CAS PubMed PubMed Central Google Scholar
Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–84. https://doi.org/10.1097/JTO.0b013e3182779d18.
Article CAS PubMed PubMed Central Google Scholar
Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560–8. https://doi.org/10.1016/j.jtho.2018.06.019.
Article PubMed PubMed Central Google Scholar
Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186–94. https://doi.org/10.1016/j.lungcan.2020.03.014.
Heymach J, Negrao M, Robichaux J, Carter B, Patel A, Altan M, et al. Phase II trial of poziotinib for EGFR and HER2 exon 20 mutant NSCLC. J Thorac Oncol. 2018;13(10):S323–4. https://doi.org/10.1016/j.jtho.2018.08.243.
Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, et al. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov. 2021;11(7):1672–87. https://doi.org/10.1158/2159-8290.CD-20-1683.
Article CAS PubMed Google Scholar
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the chrysalis phase I study. J Clin Oncol. 2021;39(30):3391–402. https://doi.org/10.1200/JCO.21.00662.
Article CAS PubMed PubMed Central Google Scholar
Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov. 2022;12(7):1676–89. https://doi.org/10.1158/2159-8290.CD-21-1615.
Article CAS PubMed PubMed Central Google Scholar
Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, et al. TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations. Mol Cancer Res. 2019;17(11):2233–43. https://doi.org/10.1158/1541-7786.MCR-19-0419.
Article CAS PubMed PubMed Central Google Scholar
Zhao S, Zhuang W, Han B, Song Z, Guo W, Luo F, et al. Phase 1b trial of anti-EGFR antibody JMT101 and osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat Commun. 2023;14(1):3468. https://doi.org/10.1038/s41467-023-39139-4.
Article ADS CAS PubMed PubMed Central Google Scholar
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–46. https://doi.org/10.1038/s41591-018-0007-9.
Article CAS PubMed PubMed Central Google Scholar
Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, et al. Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial. J Clin Oncol. 2022;40(7):702–9. https://doi.org/10.1200/JCO.21.01113.
Article CAS PubMed Google Scholar
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program. Eur J Cancer. 2021;149:235–48. https://doi.org/10.1016/j.ejca.2021.02.038.
Article CAS PubMed Google Scholar
Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol. 2023;7(1):5. https://doi.org/10.1038/s41698-022-00338-9.
Article PubMed PubMed Central Google Scholar
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–7. https://doi.org/10.1200/JCO.2018.77.9777.
Article CAS PubMed PubMed Central Google Scholar
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2021.02.038.
Article CAS PubMed PubMed Central Google Scholar
Zhao R, Yao F, Xiang C, Zhao J, Shang Z, Guo L, et al. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population. J Pathol Clin Res. 2021;7:375–84. https://doi.org/10.1002/cjp2.208.
Article CAS PubMed PubMed Central Google Scholar
Xiang C, Ji C, Cai Y, Teng H, Wang Y, Zhao R, et al. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma. Mod Pathol. 2022;35(9):1181–92. https://doi.org/10.1038/s41379-022-01076-w.
Article CAS PubMed PubMed Central Google Scholar
Qin Y, Jian H, Tong X, Wu X, Wang F, Shao YW, et al. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020;14(8):1695–704. https://doi.org/10.1002/1878-0261.12710.
Article CAS PubMed PubMed Central Google Scholar
O’Sullivan DE, Jarada TN, Yusuf A, Hu LXY, Gogna P, Brenner DR, et al. Prevalence, treatment patterns, and outcomes of individuals with EGFR positive metastatic non-small cell lung cancer in a Canadian real-world setting: a comparison of exon 19 deletion, L858R, and exon 20 insertion EGFR mutation carriers. Curr Oncol. 2022;29(10):7198–208. https://doi.org/10.3390/curroncol29100567.
Article PubMed PubMed Central Google Scholar
Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, et al. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. Target Oncol. 2021;16(6):801–11. https://doi.org/10.1007/s11523-021-00848-9.
Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30(5):287–92. https://doi.org/10.5732/cjc.011.10106.
Article CAS PubMed PubMed Central Google Scholar
Liu L, Liu J, Shao D, Deng Q, Tang H, Liu Z, Chen X, Guo F, Lin Y, Mao M, Kristiansen K, Ye M, He J. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. Cancer Sci. 2017;108(12):2487–94. https://doi.org/10.1111/cas.13410.
Article CAS PubMed PubMed Central Google Scholar
Van Sanden S, Murton M, Bobrowska A, Rahhali N, Sermon J, Rodrigues B, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. Target Oncol. 2022;17(2):153–66. https://doi.org/10.1007/s11523-022-00868-z.
Article PubMed PubMed Central Google Scholar
Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation. Lung Cancer. 2015;87(1):14–22. https://doi.org/10.1016/j.lungcan.2014.10.014.
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–8. https://doi.org/10.1158/1078-0432.CCR-12-0912.
留言 (0)